Kainos Medicine Inc is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company is engaged in the research and development of degenerative brain disease treatments, antiviral drugs, anticancer drugs and other products. In addition, the Company is engaged in the research and development of Parkinson's disease drugs, AIDS drugs, blood anticancer drugs and other products.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Korea S.E. 2025-08-14			5-day change	1st Jan Change
1,087.00 ^KRW	-8.81%		-.--%	-

01-22	Kainos Medicine, Inc. cancelled the transaction announced on December 20, 2024	CI
25-06-02	Kainos Medicine Wins 991 Million Won Order	RE

Market Cap	35.56B 26.52M 23.75M 21.91M 19.83M 37.08M 2.53B 37.68M 261M 104M 1.32B 99.51M 97.39M 4.19B	P/E 2024	-7.24x	P/E 2025	-4.42x
Enterprise Value	32.84B 24.49M 21.93M 20.24M 18.31M 34.24M 2.33B 34.8M 241M 96.31M 1.22B 91.9M 89.95M 3.87B	EV / Sales 2024	145,655,759x	EV / Sales 2025	28,027,743x
Free-Float	70.44%	Yield 2024 *	-	Yield 2025	-

01-22	Kainos Medicine, Inc. cancelled the transaction announced on December 20, 2024	CI
25-06-02	Kainos Medicine Wins 991 Million Won Order	RE
25-03-20	Kainos Medicine, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-03-20	Kainos Medicine, Inc. announced that it has received KRW 5.77455032 billion in funding from Sc United Co. Ltd	CI
25-03-03	Kainos Medicine, Inc. announced that it expects to receive funding from Sc United Co. Ltd and other investors	CI
24-12-19	Kainos Medicine, Inc. announced that it expects to receive KRW 16.671549315 billion in funding	CI
24-11-20	Kainos Vision announced that it has received KRW 3.71742 billion in funding from Kainos Medicine, Inc.	CI
24-11-17	Kainos Vision announced that it expects to receive KRW 3.71742 billion in funding from Kainos Medicine, Inc.	CI
23-09-18	Kainos Medicine, Inc.(KOSDAQ:A284620) dropped from S&P Global BMI Index	CI
22-06-22	Kainos Medicine, Inc. announced that it has received KRW 2.00000052 billion in funding from SC United Co., Ltd.	CI
22-06-14	Kainos Medicine, Inc. announced that it expects to receive KRW 2.00000052 billion in funding from SC United Co., Ltd.	CI
22-06-10	Kainos Medicine to Raise over $37 Million via Stock Sale	MT
21-11-10	Kainos Medicine, Inc. announced that it has received KRW 12.49997346 billion in funding from MAGNA Investment Co., Ltd., Axis Investment Co., Ltd., and other investors	CI

3 years	960	7,100
5 years	960	16,475
10 years	960	33,650

Kainos Medicine, Inc. Stock

Stocks

A284620

KR7284620002

Biotechnology & Medical Research

Valuation: Kainos Medicine, Inc.

Latest news: Kainos Medicine, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Kainos Medicine, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
Ki-Sub Lee CEO	Chief Executive Officer	75	2007-06-14
Eun-Hui Kim PRN	Corporate Officer/Principal	68	2025-03-30
Hoo-Rok Lee AUD	Comptroller/Controller/Auditor	54	2025-03-30

Director	Title	Age	Since
Ki-Sub Lee CHM	Chairman	75	-
Byung-Jae Kim BRD	Director/Board Member	65	2023-03-30
Eun-Hui Kim BRD	Director/Board Member	68	2025-03-30

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
6/12/24	Ki-Sub Lee	Don	Chief Executive Officer	500,000	1.7907%
1/26/24	Kwang-jae Choi	Others		10,486	0.0376%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KAINOS MEDICINE, INC.	-8.81%	-.--%	-.--%	-65.92%	26.45M
WUXI APPTEC CO., LTD.	+0.34%	+1.12%	+34.75%	+61.06%	64.14B
ARGENX SE	+0.98%	+2.68%	+12.25%	+82.98%	55.53B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+103.69%	53.03B
IQVIA HOLDINGS INC.	-1.43%	-1.17%	+26.27%	+52.86%	45.99B
BEONE MEDICINES AG	-0.48%	-2.80%	+18.01%	+117.99%	42.45B
REVOLUTION MEDICINES, INC.	+0.82%	+1.37%	+227.94%	+922.41%	40.45B
CELLTRION, INC.	-0.26%	-2.57%	+12.55%	+45.18%	32.25B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+88.74%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-0.44%	-2.66%	+21.87%	-11.72%	24.23B
Average	-1.02%	+4.88%	+47.07%	+139.73%	39.26B
Weighted average by Cap.	+0.03%	+3.59%	+49.21%	+160.49%

	2024	2025
Net sales	590.37 0.44 0.39 0.36 0.33 0.62 41.92 0.63 4.34 1.73 21.94 1.65 1.62 69.49	1.17K 0.87 0.78 0.72 0.65 1.22 83.2 1.24 8.61 3.44 43.54 3.28 3.21 137.91
Net income	-12.19B -9.09M -8.14M -7.51M -6.8M -12.71M -866M -12.92M -89.62M -35.75M -453M -34.12M -33.39M -1.43B	-7.78B -5.81M -5.2M -4.8M -4.34M -8.12M -553M -8.25M -57.23M -22.83M -289M -21.79M -21.32M -916M
Net Debt	-3.34B -2.49M -2.23M -2.06M -1.86M -3.49M -237M -3.54M -24.58M -9.8M -124M -9.36M -9.16M -393M	-2.72B -2.03M -1.82M -1.68M -1.52M -2.84M -193M -2.88M -19.99M -7.97M -101M -7.61M -7.45M -320M